What is the prognostic value of galectin-3 in patients with chronic heart failure?
Galectin-3 has been shown to have prognostic value in patients with chronic heart failure, as demonstrated by data from the DEAL-HF study. Plasma galectin-3 levels have been found to predict renal insufficiency and survival in systolic heart failure, and ST2 and multimarker testing has also been associated with prognostic value in acute decompensated heart failure. Galectin-3 has also been shown to complement BNP in risk stratification in acute heart failure, and has demonstrated incremental value when combined with clinical variables for mortality prediction in acutely decompensated heart failure. Furthermore, ACE inhibitors, such as lisinopril, have been shown to have beneficial effects on morbidity and mortality in chronic heart failure.